Cardio3 BioSciences , a leader in engineered cell therapy treatments, today announced the successful completion of a futility analysis for C-CureA , its lead cell therapy for congestive heart failure, currently being evaluated in a Phase III clinical trial in Europe and Israel . The Data Safety and Monitoring Board , an independent committee comprised of international experts, reviewed unblinded safety and efficacy data from CHART-1 and determined that such data did not support discontinuation of the trial on the basis of safety or futility and recommended that it continue without changes to the protocol.
http://ift.tt/1bKlvPs
http://ift.tt/1bKlvPs
No comments:
Post a Comment